ATE214072T1 - Oligonukleotid und kanzerostatisches mittel das dieses als aktiven inhaltstoff enthält - Google Patents

Oligonukleotid und kanzerostatisches mittel das dieses als aktiven inhaltstoff enthält

Info

Publication number
ATE214072T1
ATE214072T1 AT95934305T AT95934305T ATE214072T1 AT E214072 T1 ATE214072 T1 AT E214072T1 AT 95934305 T AT95934305 T AT 95934305T AT 95934305 T AT95934305 T AT 95934305T AT E214072 T1 ATE214072 T1 AT E214072T1
Authority
AT
Austria
Prior art keywords
oligonucleotide
active ingredient
agent containing
triple
gene
Prior art date
Application number
AT95934305T
Other languages
English (en)
Inventor
Ken-Ichi Matsuo
Yoshikazu Sugimoto
Norio Masuko
Yuji Yamada
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE214072T1 publication Critical patent/ATE214072T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT95934305T 1994-10-14 1995-10-13 Oligonukleotid und kanzerostatisches mittel das dieses als aktiven inhaltstoff enthält ATE214072T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6249467A JPH08113591A (ja) 1994-10-14 1994-10-14 オリゴヌクレオチド及びこれを有効成分とする制癌剤
PCT/JP1995/002113 WO1996011938A1 (en) 1994-10-14 1995-10-13 Oligonucleotide and carcinostatic agent containing the same as active ingredient

Publications (1)

Publication Number Publication Date
ATE214072T1 true ATE214072T1 (de) 2002-03-15

Family

ID=17193397

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95934305T ATE214072T1 (de) 1994-10-14 1995-10-13 Oligonukleotid und kanzerostatisches mittel das dieses als aktiven inhaltstoff enthält

Country Status (6)

Country Link
US (1) US5869246A (de)
EP (1) EP0735046B1 (de)
JP (2) JPH08113591A (de)
AT (1) ATE214072T1 (de)
DE (1) DE69525736T2 (de)
WO (1) WO1996011938A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
EP1326892A2 (de) 2000-10-12 2003-07-16 University of Rochester Zusammensetzungen die die proliferation von krebszellen hemmen
MXPA04007586A (es) 2002-02-06 2005-06-08 Vicor Technologies Inc Moleculas anti-infarto.
EP1534729A2 (de) * 2002-02-26 2005-06-01 University of Utah Research Foundation Mit bluthochdruck und virusknospung assoziierte nedd4l-varianten
US20050287648A1 (en) 2002-08-05 2005-12-29 University Of Rochester Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
IL296666A (en) 2005-03-23 2022-11-01 Genmab As Antibodies against 38cd for the treatment of multiple myeloma
US7476733B2 (en) * 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
EP1934244A2 (de) * 2005-10-06 2008-06-25 Emthrax LLC Verfahren und zusammensetzungen in verbindung mit milzbrandsporen-glycoproteinen als impfstoffe
EP2392647A1 (de) 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US20100190689A1 (en) 2006-09-21 2010-07-29 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic distrophy
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
CN101600451A (zh) 2006-12-11 2009-12-09 犹他大学研究基金会 用于治疗病理性血管生成和血管通透性的组合物和方法
US20100239596A1 (en) * 2007-08-22 2010-09-23 University Of Southern California Grp78 and tumor angiogenesis
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
JP2010538005A (ja) * 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
WO2010070380A2 (en) 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Doc1 compositions and methods for treating cancer
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
US20110262395A1 (en) 2008-05-08 2011-10-27 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
EP2370080A1 (de) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 als zieltherapeutikum bei herzkrankheiten
US20100286762A1 (en) * 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
US20110060000A1 (en) 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
WO2014093688A1 (en) 2012-12-12 2014-06-19 1Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
US10441637B2 (en) 2013-11-21 2019-10-15 Sena Research, Inc. Methods for structural determination of selenium derivatized nucleic acid complexes
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
AU2017306422A1 (en) 2016-08-03 2019-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. TLR9 targeted therapeutics
WO2019051355A1 (en) 2017-09-08 2019-03-14 Ohio State Innovation Foundation NEW MICROARN INHIBITOR THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS
US20240083990A1 (en) 2021-01-26 2024-03-14 Universite Brest Bretagne Occidentale Novel stim1 splicing variants and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU217107B (hu) * 1990-08-14 1999-11-29 Isis Pharmaceuticals Inc. Sejtek adhézióját módosító oligonukleotidok, és eljárás ezek, valamint ezeket tartalmazó gyógyszerkészítmények előállítására
WO1993015743A1 (en) 1992-02-18 1993-08-19 Baylor College Of Medicine Novel gene therapies employing antisense constructs
WO1993017125A1 (en) 1992-02-19 1993-09-02 Baylor College Of Medicine Oligonucleotide modulation of cell growth

Also Published As

Publication number Publication date
EP0735046A1 (de) 1996-10-02
JP3484198B2 (ja) 2004-01-06
DE69525736T2 (de) 2002-10-24
DE69525736D1 (de) 2002-04-11
EP0735046B1 (de) 2002-03-06
JPH08113591A (ja) 1996-05-07
US5869246A (en) 1999-02-09
WO1996011938A1 (en) 1996-04-25
EP0735046A4 (de) 1996-12-18

Similar Documents

Publication Publication Date Title
ATE214072T1 (de) Oligonukleotid und kanzerostatisches mittel das dieses als aktiven inhaltstoff enthält
WO2003013437A3 (en) Compositions and methods for the prevention and treatment of huntington's disease
ZA979961B (en) 5-HT1F agonists
MXPA04000179A (es) Oligonucleotidos sinteticos de hebra doble para inhibicion especifica de expresion de gene.
IL189629A0 (en) Compositions containing human ctla-4 antibodies
WO2001047944A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
NO983716D0 (no) Metoksyetoksy oligonukleotider for modulering av protein-kinase C ekspresjon
PT1053313E (pt) Oligonucleotidos ''antisense'' optimizados complementares de sequencias de dna metiltransferase
PT1056454E (pt) Utilizacao de compostos macrolido para o tratamento do glaucoma
ATE299179T1 (de) Menschliche suppressor trna oligonukleotide und verfahren für deren verwendung
EP1123414A4 (de) Antisense modulation der expression von integrin alpha 4
AU2002303817A1 (en) Compositions and methods for treating or preventing convulsions or seizures
EP0932613A4 (de) Expressionsblockierung von virulenten faktoren in s. aureus
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
DE69534197D1 (de) Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält
IL135634A0 (en) 5-htif agonists
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
DE69332375D1 (de) Hundecoronavirus s gen und verwendung davon
WO2001040521A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2001048245A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2002024864A3 (en) Antisense modulation of syntaxin 4 interacting protein expression
FR2798138B1 (fr) Clonage, expression et caracterisation du gene spg4 responsable de la forme la plus frequente de paraplegie spastique autosomique dominante
AU7402600A (en) New sequence variants of the human beta1-adrenoreceptor genes and use thereof
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties